Tumor Control Durable With Pembrolizumab in Merkel Cell Cancer

28 of 50 advanced MCC patients responded; 24 - month overall survival rate was 68.7 percent
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Journal, Source Type: news